Media Releases

PhRMA Statement on Certification of Korea-U.S. Free Trade Agreement

Washington, D.C. (February 21, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement on the certification of the Korea-U.S. Free Trade Agreement: “The Korea-U.S. Free Trade Agreement recognizes the 60 years of partnership between our two countries and the important national security ties that we share. This agreement will play a key role in strengthening the U.S. economy and increasing American jobs and exports. “PhRMA has long viewed the Korea-U.S. Free Trade Agreement as an important opportunity for Korean patients to access biopharmaceutical medicines produced in the United States. With rising living standards and increasingly sophisticated access to information, Korean patients...

Latest Releases

PhRMA Statement on Certification of Korea-U.S. Free Trade Agreement

2/22/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement on the certification of the Korea-U.S. Free Trade Agreement:

PhRMA Statement on Sunshine Proposed Rule

2/17/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett today issued the following statement on implementation of the Physician Payment Sunshine provision of the Affordable Care Act:

PhRMA Statement on the President’s Fiscal Year 2013 Budget

2/13/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement on the President’s budget proposal:

Collaborations Between Public and Private Sector Are Critical to Advance Alzheimer’s Research

2/7/2012

The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani responded to new efforts unveiled today by the Administration to combat Alzheimer’s Disease

More Than 50 Medicines in Development for COPD, Third Leading Cause of Death in U.S.

2/1/2012

America’s biopharmaceutical research companies are working on 54 medicines to treat chronic obstructive pulmonary disease (COPD), according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). These exciting therapies are in late-stage development, meaning they are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

2/1/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President for Scientific and Regulatory Affairs Dr. David E. Wheadon issued the following statement today:

Your name
Your email
Recipient email(s) (separated by commas)
Subject